[go: up one dir, main page]

GB201618424D0 - Treatment of antibody mediated disease - Google Patents

Treatment of antibody mediated disease

Info

Publication number
GB201618424D0
GB201618424D0 GBGB1618424.4A GB201618424A GB201618424D0 GB 201618424 D0 GB201618424 D0 GB 201618424D0 GB 201618424 A GB201618424 A GB 201618424A GB 201618424 D0 GB201618424 D0 GB 201618424D0
Authority
GB
United Kingdom
Prior art keywords
treatment
mediated disease
antibody mediated
antibody
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1618424.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argenix bvba
Original Assignee
Argenix bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenix bvba filed Critical Argenix bvba
Priority to GBGB1618424.4A priority Critical patent/GB201618424D0/en
Publication of GB201618424D0 publication Critical patent/GB201618424D0/en
Priority to PCT/EP2017/077966 priority patent/WO2018083122A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB1618424.4A 2016-11-01 2016-11-01 Treatment of antibody mediated disease Ceased GB201618424D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1618424.4A GB201618424D0 (en) 2016-11-01 2016-11-01 Treatment of antibody mediated disease
PCT/EP2017/077966 WO2018083122A1 (en) 2016-11-01 2017-11-01 Human fcrn binding antibody for use in treatment of antibody mediated disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1618424.4A GB201618424D0 (en) 2016-11-01 2016-11-01 Treatment of antibody mediated disease

Publications (1)

Publication Number Publication Date
GB201618424D0 true GB201618424D0 (en) 2016-12-14

Family

ID=57963530

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1618424.4A Ceased GB201618424D0 (en) 2016-11-01 2016-11-01 Treatment of antibody mediated disease

Country Status (2)

Country Link
GB (1) GB201618424D0 (en)
WO (1) WO2018083122A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152546A (en) 2013-12-24 2022-11-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Fcrn antagonists and methods of use
MX2020005981A (en) * 2017-12-08 2020-08-24 Argenx Bvba USE OF CRFN ANTAGONISTS FOR THE TREATMENT OF GENERALIZED MYASTENIA GRAVIS.
CN112513073A (en) * 2018-06-08 2021-03-16 阿根思公司 Compositions and methods for treating immune thrombocytopenia
JP7565951B2 (en) 2019-06-07 2024-10-11 アルジェニクス ビーブイ Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
US20210024620A1 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
US12403175B2 (en) 2020-01-08 2025-09-02 argenx BV Methods for treating pemphigus disorders
JP2025512483A (en) 2022-04-13 2025-04-17 オーエスイー・イミュノセラピューティクス A novel class of molecules for selectively eliminating antibodies
WO2023242372A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn/hsa binding molecules and methods of use
TW202432178A (en) * 2023-01-06 2024-08-16 比利時商阿根思公司 Methods for treating pots using fcrn antagonists
WO2025096432A1 (en) * 2023-10-30 2025-05-08 Q32 Bio Inc. Treatment of anca-associated vasculitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606378A1 (en) * 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
US8273351B2 (en) * 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR20220152546A (en) * 2013-12-24 2022-11-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Fcrn antagonists and methods of use
HUE056775T2 (en) * 2015-03-09 2022-03-28 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Also Published As

Publication number Publication date
WO2018083122A1 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
IL264674B1 (en) Anti-siglec-7 antibodies for the treatment of cancer
IL256175A (en) Use of exosomes for the treatment of disease
IL253945A0 (en) Kdm1a inhibitors for the treatment of disease
PT3212233T (en) Combination therapy for treatment of disease
PL3283527T3 (en) COMBINED TREATMENT OF CANCER
GB201618424D0 (en) Treatment of antibody mediated disease
HUE059694T2 (en) Preparation for the treatment of cancer
SG11201701723XA (en) Methods of treating liver disease
MA41449A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCERS
SG11201609652RA (en) Treatment of polybacterials infections
HUE060517T2 (en) Procedures for the treatment of immunodeficiency disease
IL256103B (en) Compounds and methods for the treatment of celiac disease
LT3119384T (en) TREATMENT OF INTRAHEPATIC CHOLESTAIN DISEASES
GB201716733D0 (en) Treatment of SMC mediated disease
IL257764B (en) Methods of treating diseases
GB201516905D0 (en) Treatment of Neurodegenerative diseases
IL256000A (en) The quantification of the her 2 protein for optimal cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
EP3145931A4 (en) Treatment of autoimmune disease
PL3484475T3 (en) 1-methylnicotinamide for the treatment of cardiovascular disease
IL253847A0 (en) Methods of treating diseases
KR20180084983A (en) Uses of Pyrimido-Pyrimidazinone for the Treatment of Cancer
GB201607388D0 (en) Treatment of impulsivity-related disorders
HUE063820T2 (en) Methods for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)